Arrowhead Pharmaceuticals’ (ARWR) “Overweight” Rating Reaffirmed at Piper Sandler

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “overweight” rating reaffirmed by analysts at Piper Sandler in a report released on Thursday,Benzinga reports. They currently have a $126.00 price target on the biotechnology company’s stock, up from their previous price target of $110.00. Piper Sandler’s price target suggests a potential upside of 43.66% from the company’s previous close.

A number of other brokerages also recently issued reports on ARWR. Stifel Nicolaus assumed coverage on Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price objective on the stock. Sanford C. Bernstein boosted their target price on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $78.00 to $100.00 in a research note on Tuesday, April 21st. Royal Bank Of Canada raised their price target on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Finally, Leerink Partners lifted their price target on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $92.17.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR traded down $0.99 during mid-day trading on Thursday, hitting $87.71. 319,804 shares of the stock traded hands, compared to its average volume of 2,487,692. The business’s 50-day moving average price is $77.62 and its 200 day moving average price is $69.73. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41. The company has a market cap of $12.35 billion, a PE ratio of -40.83 and a beta of 1.26. Arrowhead Pharmaceuticals has a 12-month low of $15.01 and a 12-month high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.17. The firm had revenue of $73.74 million during the quarter, compared to the consensus estimate of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The business’s quarterly revenue was down 86.4% compared to the same quarter last year. During the same period last year, the firm earned $2.75 EPS. On average, analysts expect that Arrowhead Pharmaceuticals will post -3.09 EPS for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Hongbo Lu sold 2,970 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the sale, the director owned 52,012 shares in the company, valued at approximately $3,998,682.56. This trade represents a 5.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Tsfg LLC purchased a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at about $25,000. Optiver Holding B.V. lifted its stake in Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares during the last quarter. Versant Capital Management Inc boosted its holdings in shares of Arrowhead Pharmaceuticals by 285.1% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 80.6% in the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 154 shares in the last quarter. Finally, iSAM Funds UK Ltd bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $29,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals News Roundup

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead announced topline Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran, with the studies meeting the primary endpoint of triglyceride reduction versus placebo and showing encouraging safety and efficacy data. Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
• Positive Sentiment: Analysts responded to the trial win by raising price targets, including Chardan Capital increasing its target to $115 from $90 and reiterating a buy rating, reflecting higher confidence in plozasiran’s commercial potential. Benzinga report on price target increase
• Positive Sentiment: Investor sentiment improved further as coverage highlighted that plozasiran may support broader FDA approval and expand Arrowhead’s opportunity in the lipid-lowering market, where it could compete with Ionis’s Tryngolza. Seeking Alpha report on late-stage trial win
• Neutral Sentiment: Arrowhead also provided an update on its early-stage ARO-033 first-in-human study, with initial safety progress noted, though this is less immediately important to the stock than the plozasiran data. TipRanks ARO-033 trial update

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.